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ABSTRACT
Background: Metabolic syndrome is characterized by insulin resistance and hyperglycemia. The
molecular mechanism(s) underlying this alteration in skeletal muscle, liver, kidneys and heart in
metabolic syndrome patients are presently unclear. Recent data have demonstrated that the p38
and extracellular-signal-regulated kinases (ERK 1/2) - mitogen-activated protein kinase (MAPK)
proteins may be involved in the regulation of (Glucose transporter type 4) GLUT4 expression
levels. Other data have suggested that miRNA may also play a role. Purpose: The purpose of this
study is to compare the tissue content, phosphorylation of protein kinases (AKT), p38, c-JUN Nterminal kinase(JNK), ERK1/2, GLUT4 and transcriptional factor Myocyte enhancer factor-2
(MEF2) in the skeletal muscle, heart, liver and kidney of insulin resistant obese (fa/fa) and lean
Zucker rats. Methods: Skeletal muscle, heart, liver and kidney were obtained from obese (n=6)
and lean (n=6) Zucker rats. The amount and phosphorylation status of AKT, p38, JNK, ERK 1/2,
GLUT4 and MEF2 were evaluated by immunoblotting. Results: Decreased GLUT4 expression
levels were observed in the skeletal muscle, liver and heart of obese Zucker rats compared to lean
zucker rats and are associated with alterations in the phosphorylation of MAPK family members.
Levels of mir-1and 133a were altered in skeletal and cardiac muscles of obese Zucker rats when
compared with their lean counterparts. Conclusions: These results suggest that MAPK members
regulate GLUT4 expression differently in various insulin resistant tissues compared to lean
counterparts and that these changes may play a key role in insulin resistance associated with
glucose dysregulation.
Key words: Insulin resistance, Akt, P38, Erk1/2, JNK, MEF2, GLUT4
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CHAPTER 1

Introduction
According to the World Health Organization diabetes fact sheet for January 2011
approximately 220 million people worldwide have diabetes and it is estimated that this will rise
to 366 million by 2030. The Centers for Disease Control and Prevention has estimated that
about 8.3 percent of the total United States populations are diabetic. Diabetes mellitus (DM) is a
serious, life-threatening condition that is characterized by high levels of blood glucose resulting
from defects in insulin production, insulin action, or both [1]. Individuals with type 2 diabetes
typically exhibit characteristics of metabolic syndrome and insulin resistance characterized by
hyperinsulinemia, hyperlipidemia and hyperglycemia [2]. The obese Zucker (fa/fa) rats are leptin
deficient models that result in an early onset of type 2 diabetes and exhibit the characteristics of
metabolic syndrome and are therefore thought to be an appropriate model for diabetes related
studies.
Metabolic syndrome is associated with alterations in insulin signaling that can lead to
insulin resistance and hyperglycemia [3]. Insulin resistance is the cause of type 2 diabetes thatis
linked with several other factors and plays a key role in pathogenesis of metabolic syndrome [3].
A key regulator of insulin induced glucose uptake is the glucose transporter (GLUT4) [4]. It is
thought that the GLUT4 is regulated, at least in part, by PI3K that, when phosphorylated causes
recruitment of protein kinase B (PKB) and PDK1 [5]. There is overwhelming evidence to
support the role of Akt/PKB in insulin stimulated glucose uptake [6-8]. Mitogen activated
protein kinases are also thought to play a role in the GLUT4 expression and relocation. The
stress-responsive kinase, p38 mitogen-activated protein kinase (p38-MAPK), ERK1/2 (extra
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signal regulatory kinases) have been found to be involved in the regulation of GLUT4 expression
by activating the transcription factor MEF2 that, in turn, activates the GLUT4 promoter [9].
Though it is well established that insulin resistance is associated with glucose dysregulation,
whether differences exist between normal and insulin resistant tissues in the regulation of MAPK
members and GLUT4 levels remains unclear. To our knowledge, the mechanism of insulin
signaling in different sensitive tissues like skeletal muscle, liver, heart and kidney of normal and
diabetic animal has not been investigated.

Purpose
Our long-term goal is to elucidate the organ specific differences in insulin induced
signaling in lean and obese Zucker rats that could provide vital information in further
understanding the molecular mechanisms and drug targets of insulin resistance. The objective of
this study is to determine whether insulin resistance alters insulin related signaling mechanisms
differently in skeletal muscle, liver, kidneys and heart. To achieve the objective we will compare
the tissue content of phosphorylated levels of AKT, p38 mitogen activated protein kinases, JNK
(c-Jun N-terminal kinases), ERK1/2 (extracellular regulatory kinases), GLUT4 (glucose
transporter) and transcriptional factor Myocyte enhancer factor-2 (MEF2) in the skeletal muscle,
heart, liver and kidney of Obese (fa/fa) and Lean Zucker rats. We will also investigate the role
of different microrna in regulation of GLUT4 expression in type 2 diabetes that might be useful
in designing therapeutic targets.
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Specific Aims
Estimated global healthcare expenditures to treat and prevent diabetes and its
complications are expected to total US Dollar (USD) 376 billion in 2010. By 2030, this number
is projected to exceed some USD 490 billion (International diabetes federation, diabetes atlas).
Diabetes is the sixth leading cause of death in the US. The economic burden posed by diabetes is
daunting with the total cost of diabetes in the U.S. in 2007 at an estimated 174 billion and this
cost is estimated to almost triple in the next 25 years (American Diabetes Association). As such,
it is clear that the scientific community must continue to search for the most effective methods
for the treatment and prevention of this disease. Recent data have suggested that the p38 and
extracellular-signal-regulated kinases (ERK 1/2)-mitogen-activated protein kinase (MAPK)
proteins may be involved in the regulation of (Glucose transporter type 4) GLUT4 expression
levels. As of yet no concrete study has been done to indicate whether differences exist in insulin
signaling in different insulin resistant tissues. The working hypothesis of this study is that
differences exist between normal and diabetic skeletal muscle, heart, liver, kidney in the insulin
signaling pathway. To test this hypothesis and accomplish the purpose of this study the following
specific aims are proposed:

Specific Aim #1
To determine if the expression of total and phosphorylated levels of Akt, MAPK family,
MEF2, GLUT4 pathway related proteins and mir-1,133a, 223 miRNA are altered in the skeletal
and cardiac muscles of lean and obese Zucker rats with type 2 diabetes.
Hypothesis:
Type 2 diabetes will be associated with alterations in the expression of total and
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Phosphorylated level of Akt, MAPK family, MEF2, GLUT4 pathway related proteins and
mir-1,133a, 223 miRNA in the skeletal and cardiac muscles of lean and obese Zucker
rats.

Specific Aim #2
To determine if the expression of total and phosphorylated levels of Akt, MAPK family,
MEF2, GLUT4 pathway related proteins and mir-223 miRNA are altered in the liver of lean and
obese Zucker rats with type 2 diabetes.

Hypothesis:
Type 2 diabetes will be associated with alterations in the expression of total and
Phosphorylated levels of Akt, MAPK family, MEF2, GLUT4 pathway related proteins
and mir-223 miRNA in the liver of lean and obese Zucker rats.

Specific Aim #3
To determine if the expression of total and phosphorylated level of Akt, MAPK family,
MEF2, GLUT4 pathway proteins are altered in the kidney of lean and obese Zucker rats with
type 2 diabetes.

Hypothesis:
Type 2 diabetes will be associated with alterations in the expression of total and
Phosphorylated levels of Akt, MAPK family, MEF2, GLUT4 pathway proteins in the
kidney of lean and obese Zucker rats
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CHAPTER 2

Review of Literature
Introduction
A review of the literature pertaining to this study will be discussed here in this chapter in
detail. The following topics that are aptly related will be addressed: 1) Type 1 and Type 2
diabetes, 2) models of metabolic syndrome, and 3) regulation of glucose uptake in different
insulin sensitive tissues.

Type 1 and Type 2 diabetes
Diabetes mellitus (DM) is an emerging epidemic in United States and the world over that,
if allowed to proceed unchecked, can progress into a deadly metabolic syndrome affecting
almost all the vital organs in the body. Diabetes mellitus can be described as the uncontrolled
regulation of circulating glucose levels that is oftentimes dues to a failure in insulin production
or unresponsiveness of the tissues to insulin stimulation [10]. According to the World Health
Organization, approximately 3.4 million people died from consequences of high blood sugar in
2004. It is currently estimated that 346 million people suffer from diabetes worldwide. Here in
the United States, the American Diabetes Association has estimated that the total number of
people with diabetes in 2011 will be approximately 25.8 million, or 8.3% of the total population.
It is also estimated that the number of people exhibiting pre-diabetes in the United States will be
79 million by the end of 2011.
Type 1 diabetes mellitus is characterized by failure of pancreatic islets of Langerhans to
produce adequate amounts of insulin. Type 1 diabetes mellitus is an autoimmune mediated

5

disease that occurs in 1 of every 300 individuals in United States although it may sometimes be
due to idiopathic nature [11]. Type I diabetes is commonly diagnosed in children and hence
commonly referred to as juvenile onset diabetes or insulin dependent diabetes mellitus. This
disorder represents about five to ten percent of all recorded diabetic cases. Currently there is no
cure for type I diabetes [12].
Type 2 diabetes mellitus is characterized by insulin resistance where the responsiveness
of the target tissues to circulating levels of insulin is decreased [13]. In Type 2 diabetes there is a
gradual change from normal glucose tolerance to abnormal glucose tolerance. This shift in
tolerance is characterized at first by an increase in postprandial glucose levels that gradually
increases to hyperglycemia [14]. Previous studies have shown that genetics, obesity, physical
inactivity and environmental factors pose as risk factors for development of Type 2 diabetes
[15]. Recent studies have demonstrated that insulin resistance is associated with changes in
GLUT4 expression and alterations in insulin receptor isoform expression and IGF-I receptor
abundance [16, 17]. Other work has suggested that that impaired phosphorylation of IRS-1
receptor and reduced PI3Kinase activity may also play a role in mediating insulin resistance in
skeletal muscle [18]. Whether a similar mechanism is present in other tissue types has, to our
knowledge, not been investigated.

Summary
Type I diabetes mellitus is primarily due to an autoimmune disease in which the beta
cells of the pancreas are destroyed leading to diminished insulin production. Type I diabetes
comprises of about five to ten percent of all diabetic cases whereas Type II diabetes comprises
about ninety to ninety five percent. Type II diabetes mellitus occurs primarily due to a failure of
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cells to respond to insulin. Although the exact mechanism(s) are currently unclear, Type 2
appears to be associated with changes in receptor isoforms and the propagation of intracellular
signaling.

Models of metabolic syndrome
A suitable experimental model is a prerequisite for the success of any scientific study.
The selection of model depends primarily on the study and its potential applications. Research
centered toward diabetes has widely used rodent models for study due to their short life span and
the ability to control the external environment.
There are several strains of rodents for diabetic research such as Goto-Kakizaki rat, nonobese diabetic rats, Nagoya-Shibata-Yasuda mouse, Pound mouse, obese Zucker rats and others
[19]. The selection of particular model among these is typically dependent upon the type of
diabetes being investigated and the dependent variables that are being measured. For example the
Non-Obese Diabetic (NOD/NHsd) rats serve as a model for research in Type 1 diabetes mellitus
as they develop insulitis due to leukocytic infiltration of pancreatic islets [20]. In addition, the
onset of diabetes in these rats is associated with glycosuria and non-fasting hyperglycemia. The
Goto-Kakizaki (GK) rat is a non-obese Wistar sub strain which develops Type 2 diabetes and
exhibits hyperinsulinemia, insulin resistance, neuropathy, retinopathy and nephropathy [21].
Similarly, the Nagoya-Shibata-Yasuda mouse develops spontaneous non-insulin-dependent
diabetes. This model is particularly suitable for studying the genetics of diabetes [22]. In
addition, this strain also exhibits some characteristics of diabetes seen in humans including
impaired insulin secretion, visceral fat accumulation and the ability to induce development of
this disease by dietary manipulation. Another model for type 2 diabetic is the Israel Sand rat or
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Psammomys obesus, which belongs to the gerbil family [23]. These rats exhibit impaired insulin
sensitivity accompanied by increased adiposity before the onset of insulin resistance in a manner
that closely resembles human type 2 diabetes [23]. Another strain that has also been developed is
the

Pound mouse (C57BL/6NCrl-Leprdb-db/Crl), which exhibits hyperinsulinemia, insulin

resistance, dyslipidemia, metabolic syndrome, leptin deficiency and fatty liver disease [24]. This
strain develops hyperinsulinemia by 8 weeks of age with insulin levels exceeding 300 ng / ml by
18 weeks.

Obese Zucker rat model
The most commonly and perhaps best suited model for type 2 diabetes study is the obese
Zucker rat that was developed through selective breeding over many generations. These animals
exhibit hyperinsulinemia, hyperphagia, hypercholesterolemia and hyperglycemia along with
central obesity[25]. These animals are also considered to be excellent models for the study of
metabolic syndrome as they also exhibit glucose intolerance, insulin resistance, increased
oxidative stress in heart and liver, borderline hypertension, cardiac hypertrophy and increased
mean arterial pressure [25-27]. Other characteristics include increased hepatic glycogen,
impaired glycogen synthesis, steatosis and proteinuria, peripheral neuropathy and altered
sympathetic and parasympathetic activity [28]. Taken together, these data suggest that the obese
Zucker is highly suited for the study of Type 2 diabetes and metabolic syndrome.
Earlier studies on the hearts of obese Zucker rats demonstrated that the hyperphosphorylation of IRS-1 may significantly contribute to pathogenesis of insulin resistance in the
heart [29]. They also correlated the alterations in insulin-induced glucose transport activation and
GLUT4 translocation to possible defects of the insulin signaling cascade [29]. Carvalho et al.,
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demonstrated that insulin resistance in the adipocytes of obese Zucker rats is characterized by
impaired glucose transporter 4 (GLUT4) translocation and diminished GLUT4 expression due to
signaling defects associated with reductions in protein kinase B (AKT) and PI3K activation [30].

Summary
Millions of Americans have been diagnosed with type 2 diabetes, and many more are
unaware that they are at high risk. The obese Zucker (fa/fa) rat appears to be an appropriate
animal model for studying diabetes given its phenotypic properties and the similarities to that
seen in humans. Few studies have investigated molecular mechanisms that are responsible for
insulin resistant in the obese Zucker rat model. Elucidating the molecular events responsible for
insulin resistance may be beneficial designing pharmacological interventions for the treatment of
this disease.

Regulation of glucose uptake in different vital organs
A major metabolic defect associated with type 2 diabetes is the failure of tissues in the
body to properly utilize glucose, thereby resulting in chronic hyperglycemia. Given that
elevations in blood glucose levels can be toxic, it is of importance to understand the underlying
molecular mechanisms that regulate insulin resistance. In the early 1980s, Dr. Cushman and
colleagues proposed a novel mechanism in which vesicles containing glucose transporters could
be mobilized to the plasma membrane by insulin stimulation , thereby effecting glucose transport
into the cell [31]. Subsequent studies have largely confirmed this initial work and have begun to
unravel the signaling mechanisms responsible for regulating glucose transporter movement to the
cell membrane.
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A key regulator of insulin-induced glucose uptake is the glucose transporter (GLUT4).
GLUT4 is primarily expressed in skeletal muscle and adipocytes. Under conditions of low
insulin, GLUT4 is sequestered in intracellular vesicles. Conversely, when insulin levels are
increased, translocation of GLUT4 transporters occurs. This process appears to be initiated by
insulin binding to the insulin receptor that then activates the receptor's tyrosine-kinase domain.
The receptor, now activated, in turn phosphorylates the insulin receptor substrate-1 (IRS-1) that,
in turn, binds the enzyme PI-3 kinase. PI-3 kinase then activates protein kinase B (AKT) through
its phosphorylation. Activation of AKT through an as of yet underdetermined mechanism, then
induces the movement of GLUT4 containing vesicles from the cytoplasm to the plasma
membrane.

Intracellular signaling pathways that regulate GLUT4 activity and expression
The mitogen-activated protein kinases (MAPK) are serine/threonine-specific protein
kinases that respond to extracellular stimuli. The MAPK proteins, when activated function to
regulate various cellular activities including gene expression, differentiation, proliferation, and
cell survival or apoptosis [32]. The p38-MAPK is a mammalian orthologue of the yeast Hog1p
MAP kinase, which participates in a signaling cascade controlling cellular responses to cytokines
and stress. There are four different isoforms of p38 MAPK: α, β, γ and δ. Previous studies have
shown that hyperglycemia can activate p38 kinase in a protein kinase C (PKC) - δ isoformdependent manner [33]. Michelle et al., in 2003 proposed a model in which GLUT4
translocation by insulin was dependent upon both AKT/PKB and p38 MAPK activation [34].
Other data have shown that extremely elevated levels of glucose can also activate p38 kinase in a
PKC-independent manner, most likely by inducing hyperosmolarity [33].
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The extracellular signal regulated kinases (ERKs) are members of the MAPK family,
which are involved in regulation of meiosis, mitosis, and in modulating gene expression. The
ERK-MAPK proteins are activated by a variety of stimuli such as growth factors, cytokines, and
carcinogens. Jing et al. showed that fatty acids can cause an increase in glucose uptake by
activation of ERK1/2.
In addition to the PI-3K, Akt and the MAPK proteins, the myocyte enhancer factor-2
transcription factor may also play a role in regulating glucose uptake through its ability to
regulate GLTU-4 protein expression. The myocyte enhancer factor-2 (MEF2) proteins are a
family of transcription factors, which control gene expression and regulate cellular
differentiation and development during the embryonic development. In adults, MEF2 is involved
in regulation of various stress responses. Thus far, four isoforms of MEF2 have been delineated:
MEF2A, MEF2B, MEF2C and MEF2D. It has been shown that p38 MAPK can phosphorylates
MEF2, ATF-2, and MAX transcription factors under different conditions. Previous studies have
shown that MEF2 protein regulates cardiac hypertrophy and tissue remodeling in skeletal muscle
in response to stress [35, 36] . Mora et al., demonstrated that cardiac and skeletal muscle
expression of GLUT4 is dependent upon a MEF2A-MEF2D heterodimer [37]. Recently,
Christophe et al., showed that activation of p38 MAPK caused an increase in the expression of
GLUT4 in response to IGF-1 in cardiac myocyte. In addition, this group also showed that MEF2
was the main transcription factor transducing the effect of p38 MAPK activation on the GLUT4
promoter [9]. Whether the mechanisms regulating the expression and activation of GLUT4
expression differ in different organs is not clear. Elucidating the molecular events responsible for
alterations in GLUT4 expression in different organs of no diabetic and diabetic animals may be
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beneficial for the development of new pharmacological interventions to treatment this Type 2
diabetes.

MicroRNAs
MicroRNAs are short ribonucleic acid molecules that act as post-transcriptional
regulators by binding to complementary sequences on target messenger RNA transcripts. This
binding, in turn, results in translational repression or target degradation. Elia et al., showed that
miR-1 controls the expression of insulin-like growth factor-1 and IGF-1 receptor protein levels
by translation in a reciprocal relationship [38]. Fred et al., showed that high glucose suppresses
human Islet insulin biosynthesis by inducing miR-133a [39]. Recently Lu et al., provided
interesting evidence with regards to regulation of glucose uptake by mir-223. They found that
over expression of miR-223 resulted in an increase in expression of glucose transporter4 (Glut4)
protein without effecting PI3Kinase or AMP Kinase activity [40]. Whether similar findings are
observed in vivo is currently unclear.

Summary
Type 2 diabetes is characterized by unresponsiveness of the cells to normal levels of
circulating insulin. GLUT4 is a primary glucose transporter protein for skeletal and cardiac
muscle. Under elevated glucose conditions, GLUT4 is translocated to plasma membrane where it
is responsible for up taking glucose into the cell. The regulation of GLUT4 function and
expression appears to be mediated by the activity of the PI3K, Akt and MAPK signaling
systems. The MEF2A transcription factor is activated by the MAPK pathways by high glucose
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levels and may participate in the regulation of GLUT4 expression levels. Recent data suggest
that miRNA may also play a role in regulating GLUT4 expression. It is currently unclear if the
regulation of GLUT4 translocation and expression is regulated similarly in different tissue types.

Figure 1. Pictorial representation of activation and translocation of GLUT4 via MAPK
family

Front Biosci. 2003 Sep 1;8:d1072-84
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Figure 2. Schematic representation of MAPK mediated GLUT4 regulation
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CHAPTER 3

Altered regulation of Mitogen-activated protein kinase (MAPK) mediated GLUT4
expression in skeletal muscle, liver, heart and kidney of Obese Zucker rat

15

ABSTRACT
Background: Metabolic syndrome is characterized by insulin resistance and hyperglycemia. The
molecular mechanism(s) underlying this alteration in skeletal muscle, liver, kidneys and heart in
metabolic syndrome patients are presently unclear. Recent data have demonstrated that the p38
and extracellular-signal-regulated kinases (ERK 1/2) - mitogen-activated protein kinase (MAPK)
proteins may be involved in the regulation of (Glucose transporter type 4) GLUT4 expression
levels. Other data have suggested that miRNA may also play a role. Purpose: The purpose of
this study is to compare the tissue content, phosphorylation of protein kinases (AKT), p38, cJUN N-terminal kinase(JNK), ERK1/2, GLUT4 and transcriptional factor Myocyte enhancer
factor-2 (MEF2) in the skeletal muscle, heart, liver and kidney of insulin resistant obese (fa/fa)
and lean Zucker rats. Methods: Skeletal muscle, heart, liver and kidney were obtained from
obese (n=6) and lean (n=6) Zucker rats. The amount and phosphorylation status of AKT, p38,
JNK, ERK 1/2, GLUT4 and MEF2 were evaluated by immunoblotting. Results: Decreased
GLUT4 expression levels were observed in the skeletal muscle, liver and heart of obese Zucker
rats compared to lean zucker rats and are associated with alterations in the phosphorylation of
MAPK family members. Levels of mir-1and 133a were altered in skeletal and cardiac muscles of
obese zucker rats when compared with their lean counterparts. Conclusions: These results
suggest that MAPK members regulate GLUT4 expression differently in various insulin resistant
tissues compared to lean counterparts and that these changes may play a key role in insulin
resistance associated with glucose dysregulation.
Key words: Insulin resistance, Akt, P38, Erk1/2, JNK, MEF2, GLUT4

16

Introduction
The Centers for Disease Control and Prevention estimates that nearly 26 million
Americans or about 8% of the total population are diabetic [10]. Diabetes remains the sixth
leading cause of death in the United States and costs $174 billion annually, including $116
billion in direct medical expenses. Perhaps most worrisome is the fact that an additional 35% of
all adults are considered pre-diabetic.
Type 2 diabetes accounts for about 90-95% of all diabetes cases and is thought to be
caused, at least in part, by insulin resistance [3]. The regulation of glucose uptake into the cell in
response to elevations in extracellular insulin is not fully understood. A key regulator of insulininduced glucose uptake is the glucose transporter (GLUT4) [4]. GLUT4 redistributes from the
intracellular membrane pool to plasma membrane upon insulin stimulation [41]. Activation of
insulin receptor by insulin is thought to stimulate the PI3-kinase pathway. The PI3-kinase, in
turn, recruits the serine/threonine protein kinases protein kinase B (PKB or Akt) and PDK1 [5],
which results in the stimulation of glucose uptake [6-8]. In addition to Akt, the mitogen activated
protein kinases (MAPK) are also thought to play a role in the GLUT4 expression and relocation.
The p38-MAPK has been found to be involved in the regulation of GLUT4 expression by
activating the transcription factor MEF2, which functions to activate the GLUT4 promoter [9].
Besides p38-MAPK, regulation of glucose uptake has also been found to be influenced by the
extracellular-regulated kinase 1/2 (ERK1/2)–MAPK as the phosphorylation of this molecule is
thought to be involved in regulating insulin receptor signaling and GLUT4 translocation [4244]. Conversely, the activation of c-Jun N-terminal Kinase (JNK) has been found to be impair
the insulin-signaling pathway by serine phosphorylation of IRS proteins [45]. How insulin
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regulated signaling and GLUT4 expression is regulated in different tissues is to our knowledge,
not been investigated.
The purpose of this study was to determine whether insulin resistance alters insulin
related signaling mechanisms differently in skeletal muscle, liver, kidney and heart. To
accomplish this goal, we examined the regulation of Akt, MAPK proteins, MEF2A and GLUT4
in normal and insulin resistant obese Zucker rats. Taken together, our findings suggest that
insulin related signaling appears to be regulated differently in different insulin sensitive tissues.

Materials and methods
Animal care
All procedures were performed as outlined in the Guide for the Care and Use of
Laboratory Animals as approved by the Council of the American Physiological Society and the
institutional animal use review board of Marshall University. Young male Lean Zucker (LZ, n
=6) and Obese Zucker (OZ, n =6) rats were obtained from the Charles River Laboratories. All
animals were 12 weeks of age at completion of this study. Rats were housed two per cage in an
American Association for the Accreditation of Laboratory Animal Care approved vivarium.
Housing conditions consisted of a 12:12-h dark-light cycle, and temperature was maintained at
22 ± 2°C. Animals were provided food and water ad libitum and allowed to recover from
shipment for at least two weeks before experimentation. During this time, the animals were
carefully observed and weighed weekly to ensure none exhibited signs of failure to thrive, such
as precipitous weight loss, disinterest in the environment, or unexpected gait alterations.
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Tissue collection
Rats were anaesthetized with a ketamine-xylazine (4:1) cocktail (50 mg/kg i/p) and
supplemented as necessary for reflexive response before tissue collections. The plantaris
muscles, liver, kidney, heart were collected, trimmed of excess connective tissue, weighed and
flash frozen in liquid nitrogen. Samples were stored at -80 °C until further analysis.

Tissue homogenization and determination of protein concentration
Muscles, liver, kidney, heart samples were homogenized in Pierce Tissue Protein
Extraction Reagent (10 ml/g tissue; Rockford) that contained protease inhibitors (P8340; SigmaAldrich, St. Louis, MO) and phosphatase inhibitors (P5726; Sigma-Aldrich). After incubation on
ice for 30 min, the homogenate was collected by centrifuging at 12,000 g for 5 min at 4°C. The
protein concentration of homogenates was determined via the Bradford method (Fisher
Scientific, Rockford, IL). Homogenate samples were boiled in a Laemmli 2X sample buffer
(Sigma-Aldrich) for 5 min.

SDS-PAGE and immunoblotting
Total protein from each sample (45µg) was separated on a 10% PAGEr Gold Precast gel
(Lonza, Rockland, ME) and then transferred to a nitrocellulose membrane. Visual verification of
transfer and equal protein loading among lanes were accomplished by Ponceau S staining of the
membranes. For immunodetection, membranes were blocked for 1 h at room temperature in
blocking buffer [5% nonfat dry milk in 20 mMTris-base, 150mM NaCl, and 0.05% Tween 20
(TBS-T), pH 7.6], serially washed in TBS-T at room temperature, and then probed with
antibodies for the detection of Akt (#9272), phospho-Akt (Ser473) (# 9271), PTEN (# 9552),
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phospho-PTEN (Ser380/Thr382/383) (#9549), p38 MAPK (#9212), phospho p38 MAPK (#
9211), P44/42 MAPK (ERK1/2) (#9102), phospho p44/42 MAPK (Thr202/Tyr204) (#9101),
SAPK/JNK (#9252), phospho SAPK/JNK (Thr183/Tyr185), MEF2A (#9736), GLUT4 (#2299)
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (#2118) (Cell Signaling Technology
,Beverly, MA). Membranes were incubated overnight at 4°C in primary antibody buffer (5%
BSA in TBS-T, pH 7.6. Primary antibody diluted 1:1,000) followed by washing in TBS-T (5 min
each), and incubation with horseradish peroxidase conjugated secondary antibody [anti-rabbit (#
7074) or anti-mouse (#7076); Cell Signaling Technology, Danvers, MA] in blocking buffer for 1
h. After removal of the secondary antibody, membranes were washed (3x5 min) in TBS-T, and
protein bands were visualized on reaction with ECL reagent (Amersham ECL Western Blotting
reagent RPN 2106; GE Healthcare Bio-Sciences, Piscataway, NJ). Target protein levels were
quantified by Alpha Ease FC image analysis software (Alpha Innotech, San Leandro, CA) and
normalized to GAPDH.

RNA extraction and miRNA analysis
Skeletal muscle, heart, kidney and liver of lean and obese Zucker rats are homogenized
Individually, on ice in a TRI reagent (Ambion, Austin, TX) at a ratio of 1 mL of TRI reagent
Per 100 mg of tissue. The homogenate was incubated for 5 minutes on ice to allow nucleoprotein
complexes to completely dissociate, and centrifuged at 4°C for approximately for 15 mins at
12,000 x g. The supernatant was separated from the pellet and transferred to a 2 ml RNAse-free
tube. A 200-µl aliquot of chloroform (Sigma-Aldrich, Inc., St. Louis, MO) was added to the
supernatant. The solution was mixed and incubated at room temperature for 10 mins, followed
by centrifugation at 4°C for 15 mins at 12,000 x g. The aqueous phase of the solution was
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collected and transferred to another tube. A 500- µl aliquot of isopropanol (Sigma-Aldrich, Inc.,
St. Louis, MO) was added to the aqueous phase, followed by thorough mixing. The resultant
solution was incubated at room temperature for 10 mins, followed by centrifugation at 4 °C for
10 minutes at 12,000 x g. The supernatant was then carefully removed without disturbing the
pellet. The RNA pellet was washed free of salts by centrifugation in 75% ethanol at 7500 x g for
5 minutes. The ethanol wash was carefully removed without disturbing the pellet, and the
residual ethanol was evaporated at room temperature by speed vacuuming for 1 minute. The
RNA pellet was dissolved in 50 µl of RNAse free water and quantified at 260 nm using a
NanoVue UV-Vis Spectrophotometer (GE Healthcare, Piscataway, NJ). The integrity of the
RNA from each sample was determined through use of RNA 6000 Nano Kit and an Agilent 2100
Bio analyzer (both from Agilent Technologies, Santa Clara, CA). Two micrograms of RNA were
reverse transcribed (RT) using the QuantiMiR RT kit (System Bioscience) according to standard
methods (Systems Bioscience). Control RT reactions were done in which the RT enzyme was
omitted. The control RT reactions were PCR amplified to ensure that DNA did not contaminate
the RNA. Cyber green-based real-time qPCR was performed by using a 7500 Real-Time PCR
system (Applied Bio systems, Foster City, CA) and gene-specific primers for the miRNA of
interest designed according to the guidelines outlined in the QuantiMiR RT kit (System
Bioscience). Melt analysis was used after each PCR run to ensure amplification of only a single
product. All samples were normalized to an internal control housekeeping gene (U1 small
nuclear RNA (snRNA)).

Relative fold changes in miRNA within each group and basal

differences between groups were determined from the Ct values after normalization to their
respective housekeeping genes using the 2∆ct method.
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Statistical analysis
Results are presented as means ± SE. Data were analyzed using the Sigma Stat 3.5
statistical program. The effects of insulin resistance on protein phosphorylation were analyzed
using a t- test. Differences were considered Significant at P < 0.05.

Results
Insulin resistance decreases muscle and liver GLUT4 levels.
GLUT4 levels were 16-, 33- and 45% lower in the obese Zucker plantaris, liver and heart,
respectively (P<0.05). Conversely, GLUT4 expression was 51% higher in the obese Zucker
kidney (P<0.05) (Figure 1).

Insulin resistance decreases the amount of Akt phosphorylation in skeletal muscle and
liver.
Compared to lean animals, the ratio of phosphorylated (Ser 473) to total Akt was 32%
and 27% lower in the skeletal muscle and liver of the obese Zucker rats (P<0.05) (Figure 2).
Conversely, the ratio of p-Akt to total Akt was 12 and 11% higher in the obese Zucker heart and
kidney (P<0.05). Compared to that observed in the lean animals, the ratio of phosphorylated
(Ser380/Thr382) to total PTEN were 19- and 10% higher in the plantaris and liver, respectively
(P<0.05) (Figure 4). Compared to that seen in the lean animals, the ratio of p-PTEN to PTEN
was 8- and 24% lower in the obese Zucker rat heart and kidney (P<0.05).
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Insulin resistance affects the phosphorylation of MAPK proteins

Compared to that observed in the lean Zucker animals, the ratio of phosphorylated p38
(Thr180/Tyr 182) 21-, 122- and 19% higher in the obese Zucker skeletal muscle, liver and
kidney, respectively (P<0.05) (Figure 3).
Compared to that seen in the lean animals, the ratio of phosphorylated ERK1/2
(Thr202/Tyr204) to total ERK1/2 levels were higher in skeletal muscle (46%) but 19- and 39%
lower in the liver and heart of the obese Zucker rats (P<0.05) (Figure 5). Similar to what we
observed for ERK1/2, the ratio of phosphorylated (Thr183/Tyr185) to total JNK was 29% higher
in skeletal muscle (29%) and 19% lower in the hearts of the obese Zucker rats compared with
their lean counterparts (P<0.05) (Figure 6). MEF2A protein levels were 17- and 19% lower in
the muscle and hearts of obese Zucker rats (P<0.05) (Figure 7).

Insulin resistance is associated with alterations in miRNA expression

The relative expression of mir-1 was 63% lower in the hearts of the obese Zucker rat
compared to that observed in the control animal (P<0.05) (figure 8) Conversely, mir-1
expression was 218% higher in the insulin resistant muscle. The expression of mir-133a was
lower in obese Zucker skeletal muscle (96%) (P<0.05) but 120% higher in the obese Zucker
heart (120%) (Figure 9). Compared to lean animals, the relative expression of mir-223 was 88and 93% lower in the skeletal and hearts of the obese Zucker animals (P<0.05). Conversely, mir223 expression was 250% higher in the liver of obese compared to lean Zucker animals (P<0.05)
(Figure 10).
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Discussion
Insulin resistance is thought to be one of the primary causes of Type 2 diabetes [1]. Liver,
skeletal muscle and fat are important insulin sensitive tissues that play a primary role in the
regulation of blood glucose levels. Impaired insulin sensitivity can affect cellular metabolism
and lead to an increased reliance on fatty acids for the production of energy. This response, while
first adaptive, can led to increased secretion of inflammatory cytokines and a further decrease in
the insulin sensitivity of other tissues [49, 50].
The primary finding of this investigation was that the mechanism of insulin resistance
appears to be regulated differently in different tissue types. Specifically, we found that the
amount of GLUT4 appeared to be lower in the muscle, heart and liver but not in the kidney of
the obese Zucker rats (Figure 1). These changes in GLUT4 expression were, in turn, associated
with alterations in Akt, MAPK, and MEF2 expression and activation that appeared to differ
between tissue types.
Insulin-stimulated translocation of GLUT4 to the cell membrane has been shown to be a
key regulator of glucose uptake [46]. King et al demonstrated that insulin resistance in
gastrocnemius muscle of obese rats is characterized by an inability to activate Glut4
translocation following insulin stimulation [47]. Similar findings have been reported by Wai et al
in hearts of obese Zucker rats who showed that the cardiac expression of GLUT4 in the plasma
membrane was depressed in the fatty Zucker rat in both the basal and insulin stimulated states
[48]. The mechanism(s) responsible for the diminished activation of GLUT4 following insulin
stimulation are not clear however recent data has demonstrated that the activation of protein
kinase B (Akt) and p38-MAPK may play a pivotal role [34].
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Herein we demonstrate that insulin resistance is characterized by decreases in the amount
of phosphorylated (activated) Akt and increases in the amount of phosphorylated p38-MAPK in
the skeletal muscle and liver of the obese Zucker rat (Figures 2 and 3). Shao and coworkers
suggested that that decreased insulin-stimulated Akt kinase activity but not MAPK is an
important component underlying impaired GLUT4 translocation and insulin resistance in skeletal
muscle of db/db mice [49]. Niu and colleagues observed that GLUT4 activity is regulated by
insulin in skeletal muscle cells during their maturation into myotubes and that this process is
related to the ability of insulin to stimulate p38 MAPK [50]. Subsequently Christophe et al found
that p38 is a strong inducer of GLUT4 expression in cardiac myocyte [9]. Taken together, these
findings suggest that the regulation of GLUT4 by p38 MAPK appears to differ across various
tissues and perhaps at different time points within the same tissue.
PTEN is a dual specificity phosphatase protein involved in tumor suppression and is a
negative regulator of the Akt signaling pathway. Previous studies have shown that muscle
specific deletion of PTEN resulted in enhanced insulin stimulated glucose uptake and Akt
phosphorylation in soleus but not in the extensor digitorum longus muscle, suggesting that the
activity of PTEN in glucose regulation is restricted to certain tissues or perhaps dependent on
other factors [51]. Shen and colleagues recently demonstrated that resistin mediated PTEN
expression is regulated by p38 MAPK signaling, which may activate target transcription factor
ATF-2 in human endothelial cells [52]. Herein, we observed that the ratio of phosphorylated to
total PTEN are increased in the obese Zucker skeletal muscle and liver but decreased in obese
hearts and kidneys (Figure 4). Whether these findings are directly related to the elevations we see
if p38 MAPK in the obese Zucker heart and liver is currently unclear.
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Besides p38 MAPK, it is also thought that ERK1/2 and JNK MAPK may also play a role
in the development of insulin resistance. Jiro and coworkers demonstrated that JNK1 results in
substantial protection from obesity-induced insulin resistance [53]. Other work has shown that
the activation (phosphorylation) of JNK-MAPK inhibits insulin signaling in the rat soleus muscle
by enhancing the phosphorylation of IRS1 at Ser 307 [54]. Bouzakri et al demonstrated that
ERK1/2 is phosphorylated to a greater extent in skeletal muscle cells in type 2 diabetic patients
and that this finding is correlated with phosphorylation of IRS-1 at Ser 636 [55] .Consistent with
this finding, we observed an elevation in the amount of phosphorylated ERK1/2, JNK -MAPK in
the skeletal muscle of the obese Zucker rats (Figure 5, 6).
Myocyte enhancer factor 2A is a member of MEF2 family transcription factors which act
as muscle-specific DNA binding proteins. Work by Martin et al., in 1998 showed that MEF2
binding activity is necessary for GLUT4 regulation in skeletal muscle and adipocytes [56].
Around this same time Zhao and colleagues found that p38 MAPK regulates MEF2A activity by
phosphorylating the MEF2A molecule at threonine residues 312 and 319 [57]. More recently,
work by Morgia and co-workers demonstrated that regulation of GLUT 4 enhancer is dependent
on MEF2 activity [58]. Consistent with the work of Martin, and our findings of decreased
GLUT4 expression in the skeletal muscle and hearts of the obese Zucker rat, we also
demonstrate that the expression of MEF2A was lower in the diabetic heart and skeletal muscle.
In addition to the potential role that different protein signaling pathways may play in the
regulation of GLUT4 emerging evidence also suggests that miRNA may also be involved.
MiRNA are short RNA molecules which act as post-transcriptional regulators by binding to
complementary mRNA sequence. Recent studies have shown that mir-133a and 223 regulate the
expression of Glut4 in cardiac myocytes [40]. Other work has shown that mir-133a expression is
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elevated in the diabetic rabbit heart [59]. In the present study we found that the expression of
mir-133a is higher while mir-223 expression is lower in the insulin resistant heart. Iai et al
conducted an extensive study and showed that mir-133a is lowered in skeletal muscle biopsies of
diabetic humans [60]. We demonstrate a similar finding here where we found that the expression
of mir-133a, and mir-223 was lower in obese skeletal muscle compared to lean skeletal muscle
[60]. Whether these changes in miRNA expression are directly related to the changes in GLUT4
we observe in the obese Zucker skeletal muscle is currently unclear.
Taken together, our data suggests that GLUT4 regulation appears to be regulated by
different mechanisms in different tissues. In skeletal muscle, diminished GLUT4 levels appear to
be correlated with decreases in Akt activation, MEF2A and mir-223 expression. In the liver,
GLUT4 appears to be regulated, at least in part, through diminished Akt and ERK1/2 MAPK
activation while in the heart, GLUT4 regulation is tied to decreased ERK1/2 MAPK, JNKMAPK, and MEF2A and mir-223 expression. Given these data, it is likely that future studies
perhaps looking at other molecules are likely needed to further understand the regulation of
GLUT4 expression in insulin sensitive tissues.
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CHAPTER 4
Conclusions

Type 2 diabetes is characterized by insulin resistance which leads to hyperglycemia.
According to the survey conducted by NIH about 72,000 people died in United States in 2007
alone due to the effects of diabetes. The main intent of the current study was to investigate how
insulin resistance affected the expression and activation of signaling molecules thought to play
key roles in the insulin- stimulated glucose uptake. The following conclusions were drawn from
the present study:

1. The skeletal muscle, heart and liver of the obese Zucker rat’s exhibits decreased GLUT4
protein expression.
2. In skeletal muscle, diminished GLUT4 levels appear to be correlated with decreases in
Akt activation, MEF2A and mir-223expression.
3. In the liver, GLUT4 appears to be regulated, at least in part, through diminished Akt and
ERK1/2 MAPK activation.
4. In the heart, GLUT4 regulation is tied to decreased ERK1/2 MAPK, JNK-MAPK,
MEF2A and mir-223 expression.
5. The kidneys of obese Zucker rat exhibit increases in GLUT4 expression which may be
related to increased p38 MAPK activation.
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Future Directions

Future directions based on this study should focus on examining other molecules thought
to be involved in the regulation of insulin sensitivity or other in vitro models which may permit
the testing of how changes in gene expression may directly affect GLUT4 protein expression.
Other work could also examine the effects of the p38 inhibitor SB-681323 on MEF2
phosphorylation and how this might affect GLUT mRNA levels.
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Figure 3. Total levels of GLUT4 are altered in diabetic rats
Total levels of GLUT4 in different tissues of lean and obese Zucker male rats at 12weeks of age.
Results are expressed as arbitrary units for comparison.GAPDH was used as an internal control.
An asterisk (*) indicates significant differences in obese Zucker rats from the lean Zucker age
matched controls (P< 0.05). Abbreviations: LM, lean skeletal muscle; OM, obese skeletal
muscle; LL, lean liver; OL, obese liver; LH, lean heart; OH, obese heart; LK, lean kidney; OK,
obese kidney.
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Figure 4. Phosphorylated to total levels of Akt are altered in diabetic rats.
Phosphorylated to total levels of Akt in different tissues of lean and obese Zucker male rats at 12
weeks of age. Results are expressed as arbitrary units for comparison. An asterisk (*) indicates
significant differences in obese Zucker rats from the lean Zucker age matched controls (P< 0.05).
Abbreviations: LM, lean skeletal muscle; OM, obese skeletal muscle; LL, lean liver; OL, obese
liver; LH, lean heart; OH, obese heart; LK, lean kidney; OK, obese kidney.
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Figure 5. Phosphorylated to total levels of p38MAPK are altered in diabetic rats.
Phosphorylated to total levels s of p38MAPK in different tissues of lean and obese Zucker male
rats at 12 weeks of age. Results are expressed as arbitrary units for comparison. An asterisk (*)
indicates significant differences in obese Zucker rats from the lean Zucker age matched controls
(P< 0.05). Abbreviations: LM, lean skeletal muscle; OM, obese skeletal muscle; LL, lean liver;
OL, obese liver; LH, lean heart; OH, obese heart; LK, lean kidney; OK, obese kidney.
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Figure 6. Phosphorylated to total levels of PTEN are altered in diabetic rats.
Phosphorylated to total levels of PTEN in different tissues of lean and obese Zucker male rats at
12 weeks of age. Results are expressed as arbitrary units for comparison. An asterisk (*)
indicates significant differences in obese Zucker rats from the lean Zucker age matched controls
(P< 0.05). Abbreviations: LM, lean skeletal muscle; OM, obese skeletal muscle; LL, lean liver;
OL, obese liver; LH, lean heart; OH, obese heart; LK, lean kidney; OK, obese kidney.
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Figure 7. Phosphorylated to total levels of ERK1/2 are altered in diabetic rats.
Phosphorylated to total levels of ERK1/2 in different tissues of lean and obese Zucker male rats
at 12 weeks of age. Results are expressed as arbitrary units for comparison. An asterisk (*)
indicates significant differences in obese Zucker rats from the lean Zucker age matched controls
(P< 0.05). Abbreviations: LM, lean skeletal muscle; OM, obese skeletal muscle; LL, lean liver;
OL, obese liver; LH, lean heart; OH, obese heart; LK, lean kidney; OK, obese kidney.
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Figure 8. Phosphorylated to total levels of JNK are altered in diabetic rats.
Phosphorylated to total levels of JNK in different tissues of lean and obese Zucker male rats at
12 weeks of age. Results are expressed as arbitrary units for comparison. An asterisk (*)
indicates significant differences in obese Zucker rats from the lean Zucker age matched controls
(P< 0.05). Abbreviations: LM, lean skeletal muscle; OM, obese skeletal muscle; LL, lean liver;
OL, obese liver; LH, lean heart; OH, obese heart; LK, lean kidney; OK, obese kidney.
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Figure 9. Total levels of MEF2A are altered in diabetic rats.
Total levels of MEF2A in different tissues of lean and obese Zucker male rats at 12weeks of age.
Results are expressed as arbitrary units for comparison. GAPDH was used as an internal control.
An asterisk (*) indicates significant differences in obese Zucker rats from the lean Zucker age
matched controls (P< 0.05).
Abbreviations: LM, lean skeletal muscle; OM, obese skeletal muscle; LL, lean liver; OL, obese
liver; LH, lean heart; OH, obese heart; LK, lean kidney; OK, obese kidney.
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Figure 10. The expression of mir-1 miRNA is altered in diabetic rats.
Ratio of expression mir-1 miRNA in different tissues of lean and obese Zucker male rats at
12weeks of age. An asterisk (*) indicates significant differences in obese Zucker rats from the
lean Zucker age matched controls (P< 0.05). Abbreviations: LH, lean heart; OH, obese heart;
LM, lean skeletal muscle; OM, obese skeletal muscle.
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Figure 11. The expression of mir-133a miRNA is altered in diabetic rats.
Ratio of expression of mir-133a miRNA in different tissues of lean and obese Zucker male rats at
12weeks of age. An asterisk (*) indicates significant differences in obese Zucker rats from the
lean Zucker age matched controls (P< 0.05). Abbreviations: LH, lean heart; OH, obese heart;
LM, lean skeletal muscle; OM, obese skeletal muscle.
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Figure 12. The expression of mir-233 miRNA is altered in diabetic rats.
Ratio of expression of mir-233 miRNA in different tissues of lean and obese Zucker male rats at
12weeks of age. An asterisk (*) indicates significant differences in obese Zucker rats from the
lean Zucker age matched controls (P< 0.05). Abbreviations: LH, lean heart; OH, obese heart;
LM, lean skeletal muscle; OM, obese skeletal muscle; LL, lean liver; OL, obese liver.
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